Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen Highlights Phase 2 Results Of Vectibix Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer
Amgen Highlights Phase 2 Results Of Vectibix Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer
Amgen Highlights Phase 2 Results Of Vectibix Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer
Submitted by
admin
on May 31, 2014 - 10:07am
Source:
Yahoo/PR NewsWire
News Tags:
Amgen
bevacizumab
colon cancer
colorectal cancer
Vectibix
Headline:
Amgen Highlights Phase 2 Results Of Vectibix Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer
Do Not Allow Advertisers to Use My Personal information
